WITHDRAWN: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma
Respiratory Medicine: X · 2020
DOI: 10.1016/j.yrmex.2020.100018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiratory Medicine: X, 2020. Verfasst von Eric D. Bateman und 10 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: AstraZeneca, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- AstraZeneca
- Regeneron Pharmaceuticals
- Teva Pharmaceutical Industries
- Sanofi Genzyme
- Boehringer Ingelheim
- Sanofi
- Schering-Plough
- Novartis
Zitieren
APA
Bateman, E. D., Khan, A. H., Xu, Y., Guyot, P., Chao, J., Kamat, S., Rowe, P., Burnett, H., Msihid, J., Weinreich, D., & Pavord, I. D. (2020). WITHDRAWN: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respiratory Medicine: X. https://doi.org/10.1016/j.yrmex.2020.100018
Vancouver
Bateman ED, Khan AH, Xu Y, Guyot P, Chao J, Kamat S, et al. WITHDRAWN: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respiratory Medicine: X. 2020. doi:10.1016/j.yrmex.2020.100018
BibTeX
@article{Bateman2020,
author = {Bateman, Eric D. and Khan, Asif H. and Xu, Yingxin and Guyot, Patricia and Chao, Jingdong and Kamat, Siddhesh and Rowe, Paul and Burnett, Heather and Msihid, Jerome and Weinreich, David and Pavord, Ian D.},
title = {WITHDRAWN: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma},
journal = {Respiratory Medicine: X},
year = {2020},
doi = {10.1016/j.yrmex.2020.100018}
}
EUVIMED